Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Immunterapi til patienter med malignt melanom og hjernemetastaser

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The risks of selective serotonin reuptake inhibitor intake in pregnancy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hjernerystelse skal tages alvorligt

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessment and treatment of cognitive impairments in patients with affective disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Chimeric antigen receptor-T-cellebehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Terapeutisk cancervaccination mod hæmatologisk cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Research output: Contribution to journalReviewResearchpeer-review

  3. Chimeric antigen receptor-T-cellebehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Line Thing Simonsen
  • Anne Mette Sjørslev Schmidt
  • Trine Heide Øllegaard
  • Inge Marie Svane
  • Lars Bastholt
  • Adam Andrzej Luczak
  • Henrik Schmidt
View graph of relations

Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.

Translated title of the contributionImmunotherapy for patients with malignant melanoma and brain metastases
Original languageDanish
JournalUgeskrift for Laeger
Volume181
Issue number24
ISSN0041-5782
Publication statusPublished - 10 Jun 2019

ID: 57728547